Posted on 02/23/2025 6:44:22 PM PST by ConservativeMind
Research led by Alberto Martini, MD, that found using antihistamines in patients receiving second-line immunotherapy (IO) for bladder cancer may improve outcomes.
The research focused on metastatic urothelial carcinoma (mUC), cancer that begins in the urothelial cells, which line the urethra, bladder, ureters and some other organs. Martini, served as corresponding author of the study.
Using data from two clinical trials, the researchers identified 896 patients who were treated with second-line IO drug atezolizumab. Out of those patients, 155 patients received concomitant antihistamines and 741 did not.
Antihistamine users had 41% lower risk for all-cause mortality, 42% lower risk for cancer death and 30% lower risk of cancer progression compared to patients that did not receive antihistamines.
"Our results show a positive association between the use of antihistamines and oncologic outcome in patients with mUC treated with IO," Martini and colleagues concluded.
(Excerpt) Read more at medicalxpress.com ...
I would tell your doctor about this study, if affected.
Bookmark
I went through immunotherapy for my liver last year. It dang near killed me. I never felt so bad in my life. The oncologist said that he was going to discontinue the therapy but I stopped it about a week before. It took until last January to feel normal. So far the tumor has shrunk and my bloodwork shows hardly any cancer plus my liver and kidney functions are normal. All I can say is that I’m not going through that again.
Bookmark
Bladder Cancer Ping
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.